| Biotechnology Entrepreneurship. LAVA Healthcare. The odds of successfully moving a new drug treatment from the lab bench to commercial approval are 5000:1.
How do innovative biotech startup companies thrive in an age of austerity to turn the odds in their favor? In this presentation, Mark Ahn, PhD, CEO of Galena Biopharma shares his views on the hype, hope, and opportunities ahead in the context of biotech industry innovation, performance and value creation. See
http://www.lava.org/events/event_details.asp?id=279490&group= |
RSS